Carriers in drug powder delivery: Implications for inhalation system design

American Journal of Drug Delivery

Volumn 3, Issue 2, 2005, Pages 117-132

  Smyth, Hugh D C ^a   Hickey, Anthony J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; LIPOSOME; NANOPARTICLE; SALBUTAMOL; SALMETEROL; TERBUTALINE;

COMPLEX FORMATION; CONTROLLED DRUG RELEASE; CRYSTALLIZATION; DEVICE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG PENETRATION; DRUG TARGETING; DRY POWDER; ELECTRICITY; ENGINEERING; HUMIDITY; INHALER; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER; PRIORITY JOURNAL; REVIEW;

EID: 22544457534     PISSN: 11759038     EISSN: None     Source Type: Journal    
DOI: 10.2165/00137696-200503020-00004     Document Type: Review

References (140)

1. Dunbar CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA 1998; 16: 7-44
2. Peart J, Clarke MJ. New developments in dry powder inhaler technology. Am Pharm Rev 2001; 4 (3): 37-45
3. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999; 16 (11): 1735-42
4. Weers J. Dispersible powders for inhalation applications. Innovations Pharm Technol 2000; 1 (7): 111-6
5. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-71
6. Crowder TM. Vibration technology for active dry-powder inhalers. Pharm Technol 2004 Apr; 28 (4): 52-61
7. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther 2003; 16 (2): 79-95
8. Zeng XM, Martin AP, Marriott C. Particulate interactions in dry powder formulations for inhalation. London: Taylor and Francis, 2001
9. Clarke MJ, Peart J, Cagnani S, et al. Adhesion of powders for inhalation: an evaluation of drug detachment from surfaces following deposition from aerosol streams. Pharm Res 2002; 19 (3): 322-9
10. Chew NY, Chan HK. The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med 2002; 15 (3): 325-30
11. Buckton G. Characterization of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv Drug Deliv Rev 1997; 26: 17-27
12. Israelachvili J. Intermolecular and surface forces. 2nd ed. New York: Academic Press, 1992
13. Hickey AJ, Concessio NM, van Oort MM, et al. Factors influencing the dispersion of dry powders as aerosols. Pharmaceutical Technology 1994 Aug; 18: 58-82
14. Trigwell S, Grable N, Yurteri CU, et al. Effects of surface properties on the tribocharging characteristics of polymer powder as applied to industrial processes. IEEE Trans Industry Applications 2001; 39 (1): 79-86
15. Hickey AJ, Dunbar CA. A new millennium for inhaler technology. Pharm Technol 1997; 21 (6): 116-25
16. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med 1993; 6 (2): 99-110
17. Clark AR. Medical aerosol inhalers: past, present, and future. Aerosol Sci Technol 1995; 22 (4): 374-91
18. De Boer AH, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers: Pt 2. Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm 1996; 138 (Jul 12): 45-56
19. Prime D, Atkins PJ, Slater A, et al. Review of dry powder inhalers. Adv Drug Deliv Rev 1997; 26 (1): 51-8
20. Steckel H, Müller BW. In vitro evaluation of dry powder inhalers: I. Drug deposition of commonly used devices. Int J Pharm 1997; 54: 19-29
21. Crowder TM, Louey MD, Sethuraman VV, et al. 2001: an odyssey in inhaler formulations and design. Pharm Technol 2001; 25 (7): 99-113
22. Gieschen LJ, Sutphen KM, Greenspan BJ, et al. Aerosol performance of dry powder inhalers (DPI): the effect of inspiratory flow rate and work done on the inhaler. Respiratory Drug Delivery VI 1998 Apr 3-7: 337-40
23. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today 1998; 1 (9): 394-8
24. Sacchetti M, van Oort MM. Spray-drying and supercritical fluid particle generation techniques. In: Hickey AJ, editor. Inhalation aerosols: physical and biological basis for therapy. New York: Marcel Dekker Inc., 1996: 337-84
25. Trofast EAC, Falk EJ, inventors. Astra Aktieholag, assignee. Agglomeration of finely divided powders. US patent US 5,551,489. 1996 Sep 3
26. Trofast EAC, inventor. Astra Aktieholag, assignee. Formulation for inhalation. US patent US 6,199,607. 2001 Mar 13
27. Steckel H, Muller BW. In vitro evaluation of dry powder inhalers: Pt 2. Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm 1997; 154 (1): 31-7
28. Braun MA, Oschmann R, Schmidt PC. Influence of excipients and storage humidity on the deposition of disodium cromoglycate (DSCG) in the twin impinger. Int J Pharm 1996; 135: 53-62
29. Kassem NM, Ho KKL, Ganderton D. The effect of air flow and carrier size on the characteristics of an inspirable cloud [abstract]. J Pharm Pharmacol 1989; 41: 14P
30. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powder for inhalation. J Aerosol Sci 1996; 27 (5): 769-83
31. Srichana T, Martin GP, Marriott C. On the relationship between drug and carrier deposition from dry powder inhalers in vitro. Int J Pharm 1998; 167: 13-23
32. Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 1998; 7 (1): 73-80
33. Mackin LA, Rowley G, Fletcher EJ. An investigation of carrier particle type, electrostatic charge and relative humidity on in-vitro drug deposition from dry powder inhaler formulations. Pharm Sci 1997; 3: 583-6
34. Chan HK, Clark A, Gonda I, et al. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm Res 1997; 14 (4): 431-7
35. Podczeck F. The relationship between physical properties of lactose monohydrate and the aerodynamic behaviour of adhered drug particles. Int J Pharm 1998; 160: 119-30
36. Vanderbist F, Wery B, Moyano-Pavon I, et al. Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent. J Pharm Pharmacol 1999; 51 (11): 1229-34
37. Clarke MJ, Tobyn MJ, Staniforth JN. The formulation of powder inhalation systems containing a high mass of nedocromil sodium trihydrate. J Pharm Sci 2001; 90 (2): 213-23
38. Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm 2004; 270 (1-2): 297-306
39. Steckel H, Furkert FH. Endotoxin testing in inhalation grade lactose-a useful quality parameter? Int J Pharm 2004; 275 (1-2): 211-5
40. Buskeyfield LJ, Jay GE, Wright P, inventors. Fisons, PLC, assignee. Pharmaceutical inhalation compositions. US patent US 5,607,662. 1997 Mar 4
41. Larhrib H, Zeng XM, Martin GP, et al. Use of different grades of lactose as a carrier for aerosolized salbutamol sulphate. Int J Pharm 1999; 191: 1-14
42. Vanderbist F, Wery B, Moyano-Pavon I, et al. Optimization of a dry powder inhalation formulation of nacystelyn, a new mucoactive agent. J Pharm Pharmacol 1999; 51: 1229-34
43. Tee SK, Marriott C, Zeng XM, et al. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int J Pharm 2000; 208: 111-23
44. Zeng XM, Martin GP, Marriott C, et al. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 2000; 200: 93-106
45. Larhrib H, Martin GP, Marriott C, et al. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm 2003; 257 (1-2): 283-96
46. Iida K, Hayakawa Y, Okamoto H, et al. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier. Chem Pharm Bull (Tokyo) 2001; 49 (10): 1326-30
47. Crowder TM, Rosati JA, Schroeter JD, et al. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2002; 19: 239-45
48. Zeng XM, Martin GP, Marriott C, et al. The influence of crystallization conditions on the morphology of lactose intended for use as a carrier for dry powder aerosols. J Pharm Pharmacol 2000; 52 (6): 633-43
49. Staniforth JN. Improvements in dry powder inhaler performance: surface passivation effects. Drug delivery to the lungs VII. London: The Aerosol Society, 1996 Dec 12-13: 86-9
50. Podczeck F. The influence of particle size distribution and surface roughness of carrier particles on the in vitro properties of dry powder inhalations. Aerosol Sci Technol 1999; 31 (4): 301-21
51. Kawashima Y, Serigano T, Hino T, et al. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm 1998; 172: 179-88
52. Flament M-P, Leterme P, Gayot A. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers. Int J Pharm 2004; 275 (1-2): 201-9
53. Chan LW, Lim LT, Heng PW. Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations. J Pharm Sci 2003; 92 (5): 975-84
54. Kassem NM, Ganderton D. The influence of carrier surface on the characteristics of inspirable powder aerosols [abstract]. J Pharm Pharmacol 1990; 42: 11P
55. Ganderton D, Kassem NM, inventors. British Technology Group Limited, assignee. Aerosol carriers. US patent US 5,376,386. 1994 Dec 27
56. Peart J, Staniforth JN, Byron PR, et al. Electrostatic charge interactions in pharmaceutical dry powder aerosols. In: Darby RN, Byron PR, Farr SJ, editiors. Respiratory drug delivery V. Buffalo Grove (IL): Interpharm Press, Inc., 1996: 85-93
57. Rowley G. Quantifying electrostatic interactions in pharmaceutical solid systems. Int J Pharm 2001; 227 (1-2): 47-55
58. Carter PA, Cassidy OE, Rowley G, et al. Triboelectrification of fractionated crystalline and spray-dried lactose. Pharm Pharmacol Comm 1998; 4: 111-5
59. Berard V, Lesniewska E, Andres C, et al. Affinity scale between a carrier and a drug in DPI studied by atomic force microscopy. Int J Pharm 2002; 247 (1-2): 127-37
60. Berard V, Lesniewska E, Andres C, et al. Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM. Int J Pharm 2002; 232 (1-2): 213-24
61. Boerefijn R, Ning Z, Ghadiri M. Disintegration of weak lactose agglomerates for inhalation applications. Int J Pharm 1998; 172 (1-2): 199-209
62. Broadhead J, Edmond Rouan SK, Rhodes CT. Deposition of spray-dried beta-galactosidase from dry powder inhaler devices. Drug Dev Ind Pharm 1996; 22: 813-22
63. Davis SS, Bubb MD. Physico-chemical studies on aerosol solutions for drug delivery. Part 3. Effect of relative humidity on the particle size of inhalation aerosols. Int J Pharm 1978; 1: 303-14
64. Duvivier DH, Chiap P, Crommen J, et al. Evaluation of some parameters influencing the drug delivery from a dry powder inhalation device using an in vitro model of the horse airways. Vet Res 1997; 28 (6): 557-64
65. Geuns ER, Toren JS, Barends DM, et al. Decrease of the stage 2 deposition in the twin impinger during storage of beclomethasone dipropionate dry powder inhalers in controlled and uncontrolled humidities. Eur J Pharm Biopharm 1997; 44: 187-94
66. Harjunen P, Lankinen T, Salonen H, et al. Effects of carriers and storage of formulation on the lung deposition of a hydrophobic and hydrophilic drug from a DPI. Int J Pharm 2003; 263 (1-2): 151-63
67. Iida K, Hayakawa Y, Okamoto H, et al. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier. Chem Pharm Bull (Tokyo) 2004; 52 (4): 444-6
68. Jashnani RN, Byron PR, Dalby RN. Testing of dry powder aerosol formulations in different environmental conditions. Int J Pharm 1995; 113 (2): 123-30
69. Jashnani RN, Byron PR. Dry powder aerosol generation in different environments: performance comparisons of albuterol, albuterol sulfate, albuterol adipate and albuterol stearate. Int J Pharm 1996; 130 (15): 13-24
70. Maggi L, Bruni R, Conte U. Influence of moisture on the performance of a new dry powder inhaler. Int J Pharm 1999; 177 (15): 83-91
71. Meakin BJ, Cainey JM, Woodcock PM. Effect of exposure to humidity on terbutaline sulfate delivery from Turbuhaler dry powder inhalation devices. Eur Respir J 1993; 6: 760-1
72. Podczeck F, Newton JM, James MB. Variations in the adhesion force between a drug and carrier particles as a result of changes in the relative humidity of the air. Int J Pharm 1997; 149: 151-60
73. Price R, Young PM, Edge S, et al. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int J Pharm 2002; 246 (1-2): 47-59
74. Harjunen P, Lehto VP, Martimo K, et al. Lactose modifications enhance its drug performance in the novel multiple dose Taifun DPI. Eur J Pharm Sci 2002; 16 (4-5): 313-21
75. Williams RO, Brown J, Liu J. Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Pharm Dev Technol 1999; 4 (2): 167-79
76. Larhrib H, Martin GP, Prime D, et al. Characterization and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolized salbutamol sulfate from dry powder inhalers. Eur J Pharm Sci 2003; 19 (4): 211-21
77. Ahlneck C, Zografi G. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int J Pharm 1990; 62: 87-95
78. Chan H-K, Chew NYK. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev 2003; 55 (7): 793-805
79. Louey MD, Stewart PJ. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharm Res 2002; 19 (10): 1524-31
80. Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm Res 1998; 15 (4): 562-9
81. Lucas P, Anderson K, Potter UJ, et al. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm Res 1999; 16 (10): 1643-7
82. Staniforth JN, inventor. Co-ordinated Drug Development Limited, assignee. Carrier particles for use in dry powder inhalers. US patent US 6,153,224. 2000 Nov 28
83. Zeng XM, Martin GP, Tee S-K, et al. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int J Pharm 1998; 176: 99-110
84. Zeng XM, Martin GP, Tee S-K, et al. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int J Pharm 1999; 182: 133-44
85. Zeng XM, Pandal KH, Martin GP. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int J Pharm 2000; 197: 41-52
86. Hino T, Kawashima Y. Particle design of dry powder inhalers. Pharm Tech Japan 1998; 14 (10): 1555-63
87. Kawashima Y, Serigano T, Hino T, et al. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharm Res 1998; 15 (11): 1748-52
88. Lucas P, Clarke MJ, Anderson K, et al. The role of fine particle excipients in pharmaceutical dry powder aerosols. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory Drug Delivery VI. Buffalo Grove (IL): Interpharm Press, Inc., 1998: 243-50
89. Islam N, Stewart PJ, Larson I, et al. Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures? Pharm Res 2004; 21 (3): 492-9
90. Clark A. Pulmonary delivery technology: recent advances and potential for the new millennium. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. 2nd ed. New York: Marcel Dekker, 2004
91. Eljamal M, Patton JS, Foster L, et al. inventors. Inhale Therapeutic Systems, assignee. Powdered pharmaceutical formulations having modified dispersibility. US patent US 6,136,346. 2000 Oct 24
92. Gordon MS, Clark A, Brewer TK, inventors. Inhale Therapeutic Systems, assignee. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients. US patent US 6,077,543. 2000 Jun 20
93. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 35: 235-47
94. Eljamal M, Patton JS, inventors. Inhale Therapeutic Systems, assignee. Methods and apparatus for pulmonary administration of dry powder alpha-1-antitrypsin. US patent US 5,993,783. 1999 Nov 30
95. Platz RM, Kimara S, Satoh Y-I, Foster L, inventors. Inhale Therapeutic Systems, assignee. Methods and compositions for the dry powder formulation of interferons. US patent US 6,123,936. 2000 Sep 26
96. Chew N, Chan H-K. Influence of particle size, air flow and inhaler device on the dispersion of mannitol powders as aerosols. Pharm Res 1999; 16 (7): 1098-103
97. Chew NYK, Bagster DF, Chan H-K. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. Int J Pharm 2000; 206 (7): 75-83
98. Trofast EA-C, Briggner L-E, inventors. Astra Aktieholag, assignee. Process for conditioning substances. US patent US 5,709,884. 1998 Jan 20
99. Clark AR, Hsu CC, Walsh AJ, inventors. Genentech Inc., assignee. Preparation of sodium chloride aerosol formulations. US patent US 5,747,002. 1998 May 5
100. Kawashima Y, Serigano T, Hino T, et al. Design of inhalation dry powder of pranlukast hydrate to improve dispersibility by the surface modification with light anhydrous silicic acid (AEROSIL 200). Int J Pharm 1998; 173: 243-51
101. Tarsin W, Corrado O, Brownlee K, et al. Inter-individual variability of peak-inhalation rates through different inhalers by asthmatic children and adults and those with COPD. Eur Respir J 2001; 18 Suppl. 33: 133s
102. Bisgaard H, Klug B, Sumby BS, et al. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998; 11 (5): 1111-5
103. Bisgaard H, Pedersen S, Nikander K. Use of budesonide Turbuhaler in young children suspected of asthma. Eur Respir J 1994; 7 (4): 740-2
104. Malmstrom K, Sorva R, Silvasti M. Application and efficacy of the multi-dose powder inhaler, Easyhaler, in children with asthma. Pediatr Allergy Immunol 1999; 10 (1): 66-70
105. Tarsin W, Assi KH, Chrystyn H. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 2004; 17 (1): 25-32
106. Joshi M, Misra AN. Pulmonary disposition of budesonide from liposomal dry powder inhaler. Methods Find Exp Clin Pharmacol 2001; 23 (10): 531-6
107. Desai TR, Wong JP, Hancock RE, et al. A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J Pharm Sci 2002; 91 (2): 482-91
108. Seville PC, Kellaway IW, Birchall JC. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J Gene Med 2002; 4 (4): 428-37
109. Arppe J, Vidgren M, Waldrep JC. Pulmonary pharmacokinetics of cyclosporin A liposomes. Int J Pharm 1998; 161 (23): 205-14
110. Sakon K, Sagagami M, Makino Y, et al. inventors. Teijin Limited, assignee. Ultrafine particle powder for inhalation and method for production thereof. US patent US 5,972,388. 1999 Oct 26
111. Sutton AD, Johnson RA, Senior PJ, et al. inventors. Quadrant Healthcare (UK) Limited, assignee. Spray-dried microparticles and their use as therapeutic vehicles. US patent US 5,993,805. 1999 Nov 30
112. Boyes RN, Tice TR, Gilley RM, et al. inventors. Innovata Biomed Limited, assignee. Pharmaceutical formulations comprising microcapsules. US patent US 5,384,133. 1995 Jan 24
113. Duddu SP, Sisk SA, Walter YH, et al. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharm Res 2002; 19: 689-95
114. Sethuraman VV, Hickey AJ. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech 2002; 3 (4): E28
115. Suarez S, O'Hara P, Kazantseva M, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 2001; 18 (9): 1315-9
116. Suarez S, O'Hara P, Kazantseva M, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother 2001; 48 (3): 431-4
117. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000; 17 (8): 955-61
118. Tsapis N, Bennett D, Jackson B, et al. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A 2002; 99 (19): 12001-5
119. Sham JOH, Zhang Y, Finlay WH, et al. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004; 269 (2): 457-67
120. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 2001; 47: 39-54
121. Edwards DA, Langer RS, Vanbever R, et al. inventors. Massachusetts Institute of Technology, assignee. US 5,985,309: Preparation of particles for inhalation. 1999 Nov 16
122. Edwards DA, Caponetti G, Hrkach JS, et al., inventors. Massachusetts Institute of Technology Penn State Research Foundation, assignee. Aerodynamically light particles for pulmonary drug delivery. US patent US 6,136,295. 2000 Oct 24
123. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998; 85 (2): 379-85
124. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997; 276 (5320): 1868-71
125. Ben-Jebria A, Chen D, Eskew ML, et al. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 1999; 16 (4): 555-61
126. Hanes J, Edwards DA, Evora C, et al. inventors. Massachusetts Institute of Technology, assignee. Particles incorporating surfactants for pulmonary drug delivery. US patent US RE37,053 E. 2001 Feb 13
127. Dunbar C, Scheuch G, Sommerer K, et al. In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int J Pharm 2002; 245: 179-89
128. Kinnarinen T, Jarho P, Jarvinen K, et al. Pulmonary deposition of a budesonide/g-cyclodextrin complex in vitro. J Control Release 2003; 90 (2): 197-205
129. Srichana T, Suedee R, Reanmongkol W. Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols: the in-vitro deposition and toxicity studies of the complexes. Respir Med 2001; 95 (6): 513-9
130. Smyth HDC, Garmise RJ, Cooney DJ, et al. Influence of physical form of Captisol® particles on performance as a dry powder aerosol carrier. Respiratory Drug Delivery IX 2004 Apr 25-29; 3: 809-12
131. Wollmer P, Backstrom K, Zhao H, et al. Surface active agents as enhancers of alveolar absorption. Pharm Res 2000; 17: 38-41
132. Kalbag S, Leone-Bay A, Maher J, et al. Enhanced Pulmonary delivery of insulin in a rat model [abstract]. AAPS PharmSci 2000; 2 (4): 1212
133. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7 (1): 49-75
134. Garcia-Contreras L, Jones LD, Hickey AJ. Alveolar macrophages: a target for drug delivery. Respiratory Drug Delivery IX 2004 Apr 25-29; 1: 33-40
135. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002; 19 (4 & 5): 425-98
136. Evora C, Soriano I, Rogers RA, et al. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2 dipalmitoylphosphatidylcholine. J Control Release 1998; 51: 143-52
137. El-Baseir MM, Kellaway IW. Poly (L-lactic acid) microspheres for pulmonary drug delivery: release kinetics and aerosolization studies. Int J Pharm 1998; 175 (15): 135-45
138. Wichert B, Rohdewald P. Low molecular weight PLA: a suitable polymer for pulmonary administered microparticles? J Microencapsul 1993; 10 (2): 195-207
139. Morimoto K, Katsumata H, Yabuta T, et al. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur J Pharm Sci 2001; 13 (2): 179-85
140. Morimoto K, Katsumata H, Yabuta T, et al. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J Pharm Pharmacol 2000; 52 (6): 611-7